How we do it

Everyone at GSK focuses on three priorities: Innovation, Performance, Trust

Dave Kilian, Oncology scientist sitting at a lab table
Dave Kilian, Oncology scientist, USA

Innovation

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

  • £3.6bn

    R&D investment in 2016

  • 3

    significant approvals in 2017 – Shingrix, Trelegy Ellipta and Juluca

  • £4.5bn

    new product sales in Pharmaceuticals and Vaccines in 2016

  • 13%

    Consumer Healthcare sales in 2016 from product innovations launched over the past three years

Dawn, pharmacist with pharmacy products on shelves in our Shopper Science Lab
Dawn Skelton, Pharmacist, UK

Performance  

We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.

  • £27.9bn

    total turnover in 2016

  • £7.7bn

    adjusted operating profit in 2016

  • £3.0bn

    free cash flow in 2016

  • £3.9bn

    dividends paid in 2016

Mother holding her baby, Ghana

Trust

We commit to ensuring the quality, safety and reliable supply of our products; and to building trust through our approach to engagement, pricing, global health and being a modern employer.

  • 8bn

    packs/doses produced in 2016

  • 86%

    of employees proud to work at GSK

  • £210m

    donated in 2016 to local communities through product donations, time and cash

  • 1st

    in Access to Medicines Index all 5 times since its launch in 2008

Our values and expectations are at the heart of everything we do and form an important part of our culture.

Our values:
Patient Focus, Transparency, Respect, Integrity

Our expectations:
 
Courage, Accountability, Development, Teamwork